Perrigo Company plc (PRGO)
Market Cap | 4.29B |
Revenue (ttm) | 4.66B |
Net Income (ttm) | -12.70M |
Shares Out | 135.52M |
EPS (ttm) | -0.09 |
PE Ratio | n/a |
Forward PE | 12.31 |
Dividend | $1.10 (3.43%) |
Ex-Dividend Date | Mar 7, 2024 |
Volume | 1,583,387 |
Open | 31.48 |
Previous Close | 31.46 |
Day's Range | 31.48 - 32.35 |
52-Week Range | 25.77 - 40.28 |
Beta | 0.62 |
Analysts | Buy |
Price Target | 39.00 (+21.16%) |
Earnings Date | May 7, 2024 |
About PRGO
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health pr... [Read more]
Full Company ProfileFinancial Performance
In 2023, PRGO's revenue was $4.66 billion, an increase of 4.58% compared to the previous year's $4.45 billion. Losses were -$12.70 million, -90.97% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PRGO stock is "Buy." The 12-month stock price forecast is $39.0, which is an increase of 21.16% from the latest price.
News
Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-ord...
Perrigo to Attend UBS Global Consumer and Retail Conference
DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduar...
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year Achieve...
Perrigo Increases its Quarterly Dividend
DUBLIN , Feb. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, announces that its Board of Directors has approved a 1% increase in t...
Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024
DUBLIN , Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 20...
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After ...
Perrigo Announces Early Results of Cash Tender Offer for Notes
DUBLIN , Nov. 29, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) (the "Company"), a leading provider of Consumer Self-Care Products, today announced the early tender results of the previously a...
Perrigo Announces Cash Tender Offer for Notes
DUBLIN , Nov. 10, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) (the "Company"), a leading provider of Consumer Self-Care Products, today announced that Perrigo Finance Unlimited Company, its ...
Perrigo's stock tumbles 14% after sales miss and lowered guidance
Perrigo Co. Plc's stock PRGO, -0.97% fell 14% early Tuesday, after the consumer self-care and wellness products maker posted weaker-than-expected third-quarter sales and lowered its guidance. Dublin, ...
Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Realized Third Quarter Double-Digit Gross Profit, Operating Income and EPS Growth Year-Over-Year Delivered Third Quarter Gross Margin and Operating Margin Expansion Year-Over-Year and Sequentially Ac...
Perrigo Announces Quarterly Dividend
DUBLIN , Nov. 2, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly divid...
Perrigo to Attend Upcoming Consumer Investor Conferences
DUBLIN , Oct. 31, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Patrick Lockwood-Taylor and CFO Edua...
Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023
DUBLIN , Oct. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2023 financial resu...
Perrigo Announces Leadership Update
Appoints Experienced Consumer Packaged Goods Executive Catherine "Triona" Schmelter as EVP and President, Consumer Self-Care Americas (CSCA) and Global Portfolio Optimization DUBLIN , Sept. 11, 2023 /...
FDA warns three baby-formula makers about production violations
The U.S. Food and Drug Administration said Wednesday it has sent warning letters to three baby-formula makers as part of what the agency called enhanced oversight of the product, which was plagued by ...
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
Achieved Year-Over-Year and Sequential Gross and Operating Margin Expansion Delivered Strong Operating Income and EPS Growth Reaffirming 2023 Outlook DUBLIN , Aug. 8, 2023 /PRNewswire/ -- Second Quar...
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
DUBLIN, Ireland , Aug. 2, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarte...
Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference
DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial res...
First nonprescription birth control pill approved in U.S.; Perrigo's Opill to hit shelves in 2024
Ibis Reproductive Health President Kelly Blanchard spoke with Yahoo Finance Live anchor Rachelle Akuffo about the FDA approval of Perrigo's Opill to be sold over the counter in the United States.
FDA Approves First Over-the-Counter Birth-Control Pill
The Food and Drug Administration approved the first over-the-counter birth-control pill, significantly expanding access to contraception among women across the U.S.
FDA approves first over-the-counter birth control pill in the U.S.; Perrigo stock jumps
Yahoo Finance Live anchors Julie Hyman and Brad Smith break down the U.S. Food and Drug Administration approving Perrigo over-the-counter birth control pill named OPill. It is the first approval of an...
FDA approves first over-the-counter birth control pill
Perrigo's Opill could significantly expand access to contraception, especially for younger women who often face logistical barriers to get birth control.
FDA Approves First Over-The-Counter Birth Control Pill in U.S. Perrigo Stock Jumps.
The drug will be available in store and online at retailers across the country 'early in the first quarter of 2024,' the company says.
Perrigo's stock soars 6% after FDA approves its over-the-counter daily oral contraceptive
Perrigo Co. PLC's stock PRGO, -0.78% soared 6% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its over-the-counter daily oral contraceptive. The...
US FDA approves Perrigo's contraceptive pill for over-the-counter use
The U.S. Food and Drug Administration on Thursday approved the over-the-counter use of Perrigo's contraceptive drug, making it the first non-prescription birth control pill in the United States.